Galenica Group half-year results 2015
Tuesday, 11 August 2015, ↓ directly to download
Galenica: Profit increase expected in 2015 for the 20th consecutive year
All Galenica Group businesses put in a very pleasing performance in the first half of 2015. In particular, Vifor Pharma managed to overcompensate the expected ceased milestone payments of about CHF 70 million through the sales-based consolidated earnings.
Although the first half of 2015 was impacted by currency exchange losses and accounting components of IAS 19, the Group management is raising the profit forecast and expects that 2015 – calculated at the average exchange rates during the first half of 2015 – will see the 20th consecutive increase in profit, both before and after minority interests.
The consolidated net sales of the Galenica Group rose by 7.9% in the first half of 2015 to CHF 1,792.3 million. Net profit before deduction of minority interests rose by 5.5% to CHF 157.8 million and net profit after deduction of minority interests declined by 2.8% to CHF 130.8 million. On a comparable basis – without currency exchange losses and accounting components of IAS 19 – net profit before deduction of minority interests rose by 13.8% to CHF 170.2 million and net profit after deduction of minority interests increased by 6.4% to CHF 143.2 million.
Sales of Ferinject® rose by 30.1% to CHF 112.1 million, whereby the number of units sold (100 mg) increased by 41%. In the USA, partner Luitpold Pharmaceuticals, Inc., posted net sales of USD 48.9 million in the first half of 2015 – already nearly matching the sales figures for the full-year of 2014. The new phosphate binder Velphoro® also performed as planned and has now been launched in the US and nine other countries.
At the end of May 2015, Galenica entered into an exclusive licensing agreement with Roche to market and distribute the Roche Mircera® product in the US and Puerto Rico. Sales generated through the distribution agreement with Roche amounted to CHF 44.7 million in the first half of 2015.
The ongoing pressure on drug prices and the rising consumer tourism due to the strong Swiss franc continue to keep the Swiss healthcare market under pressure. Nevertheless, all of the Galenica Santé Business sectors have successfully held their ground, increasing both sales and EBIT.
Per 1 September 2015, Galenica Santé will introduce a new organisational and management structure with the three Business sectors: Products & Brands, Retail and Services.
EBIT, EBITDA and consolidated net profit of the Galenica Group
in million CHF
1st half-year 2015
1st half-year 2014
Change in %
- HealthCare Information
- Eliminations Galenica Santé
Corporate and eliminations
- Shareholders of Galenica Ltd.
Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).
Tuesday, 1 December 2015
Wednesday, 30 September 2015
Tuesday, 11 August 2015
Friday, 3 July 2015
Head of Corporate Communications
Head Investor Relations